Hemostasis and Stem Cell Therapy in Myocardial Infarction

Authors

  • Ryan Ranitya Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Abstract

Cardiovascular disease has been well known as the most frequent cause of death in many countries all over the world.1 Acute myocardial infarction (AMI) is a sudden clinical coronary event that has high mortality and morbidity rate. The survivals of AMI will have left ventricle (LV) remodelling and decreased cardiac functions in the following years due to necrosis of cardiomyocites after AMI leading to chronic heart failure. However, revascularization therapy such as percutaneous coronary intervention (PCI) and medications cannot regenerate the necrotic cardiomyocites. Stem cell (SC) therapy as novel strategy in management of AMI has been developing so fast recently. Potential beneficial mechanism of SC therapy after AMI includes myocardial preservation, decreased infarct expansion and myocardial regeneration.2 To date, SC therapy in management of AMI seemed feasible and safe in clinical practice. Number of trials had been conducted to search for promising results and answers to many questions regarding the matter. The TOPCARE-AMI (transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction) with 59 patients showed improvement in ejection fraction and infarct size after 1 year follow-up. The REPAIR-AMI (reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction) trial with larger samples of 204 patients showed improvement in global LVEF at 4 months follow up from 48.3%±9.2% to 53.8%±10.2%.6 A systematic review of SC therapy in AMI with 13 RCT and 811 enrolled patients indicated LV function improvement in short term follow-up.

Downloads

Published

2016-05-16

How to Cite

Ranitya, R. (2016). Hemostasis and Stem Cell Therapy in Myocardial Infarction. Acta Medica Indonesiana, 46(1). Retrieved from http://www.actamedindones.org/index.php/ijim/article/view/56

Issue

Vol. 46 No. 1 (2014)

Section

EDITORIAL

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.